InMed Pharmaceuticals Inc...

3.26
-0.25 (-7.12%)
At close: Jan 30, 2025, 11:40 AM

Company Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies.

The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa.

The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.

In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases.

Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids.

It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics.

The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.

InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. logo
Country CA
IPO Date May 5, 2014
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Eric A. Adams B.S. Chem., M.I.B.

Contact Details

Address:
815 West Hastings Street
Vancouver, BC
CA
Website https://www.inmedpharma.com

Stock Details

Ticker Symbol INM
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001728328
CUSIP Number 457637601
ISIN Number CA4576376012
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Eric A. Adams B.S. Chem., M.I.B. President, Chief Executive Officer & Director
Michael Woudenberg P.Eng. Chief Operating Officer
N. Netta Jagpal Chief Financial Officer & Corporate Secretary
Alexandra Diane-Janet Mancini M.Sc. Senior Vice President of Clinical & Regulatory Affairs
Colin Clancy Senior Director of Investor Relations
Dr. Eric Chih-Hsien Hsu Ph.D. Senior Vice President of Preclinical Research & Development
Dr. Sazzad Hossain M.Sc., Ph.D. Co-Founder
Dr. Shane A. Johnson Ph.D. Senior Vice President & GM of BayMedica
Jerry P. Griffin Vice President of Sales & Marketing
Sarah Li CPA, CGA Vice President of Accounting & Controller

Latest SEC Filings

Date Type Title
Jan 22, 2025 8-K Current Report
Jan 21, 2025 8-K Current Report
Jan 03, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 02, 2025 424B3 Filing
Dec 30, 2024 S-1/A [Amend] Filing
Dec 23, 2024 S-1 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing
Dec 23, 2024 4 Filing